Trials / Terminated
TerminatedNCT04625764
Ticagrelor Removal Study Using CytoSorb® 300 mL Device During CPB in Patients Undergoing Emergent Cardiothoracic Surgery
A Prospective, Open, Multi-center, Single-arm Study to Demonstrate the Feasibility of the CytoSorb® 300 mL Device to Remove Ticagrelor During Cardiopulmonary Bypass in Patients on Ticagrelor Undergoing Emergent Cardiothoracic Surgery
- Status
- Terminated
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- CytoSorbents Europe GmbH · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of CyTation is to demonstrate intra-operative removal of ticagrelor by CytoSorb® hemadsorption in patients on ticagrelor undergoing emergent cardiothoracic surgery requiring CPB, using platelet reactivity to adenosine diphosphate (ADP) as a pharmacodynamics surrogate measure of ticagrelor levels in blood.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Blood sampling and analysis | Blood sampling for pharmacokinetics (Plasma ticagrelor concentrations and its metabolite) and MEA platform testing (ADPtest, TRAPtest) |
Timeline
- Start date
- 2021-02-23
- Primary completion
- 2021-10-14
- Completion
- 2021-12-14
- First posted
- 2020-11-12
- Last updated
- 2022-02-04
Locations
4 sites across 2 countries: Germany, Luxembourg
Source: ClinicalTrials.gov record NCT04625764. Inclusion in this directory is not an endorsement.